KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2025)

Historic Capital Leases for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $55.7 million.

  • Amneal Pharmaceuticals' Capital Leases fell 327.67% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 327.67%. This contributed to the annual value of $56.9 million for FY2024, which is 286.34% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Capital Leases stood at $55.7 million for Q3 2025, which was down 327.67% from $56.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Capital Leases ranged from a high of $61.9 million in Q1 2021 and a low of $55.7 million during Q3 2025
  • Moreover, its 5-year median value for Capital Leases was $59.8 million (2023), whereas its average is $59.2 million.
  • In the last 5 years, Amneal Pharmaceuticals' Capital Leases surged by 141.65% in 2021 and then crashed by 374.94% in 2025.
  • Amneal Pharmaceuticals' Capital Leases (Quarter) stood at $60.3 million in 2021, then increased by 0.86% to $60.8 million in 2022, then fell by 3.63% to $58.6 million in 2023, then fell by 2.86% to $56.9 million in 2024, then decreased by 2.14% to $55.7 million in 2025.
  • Its Capital Leases stands at $55.7 million for Q3 2025, versus $56.0 million for Q2 2025 and $56.6 million for Q1 2025.